Impact of sarcopenia indexes on survival and severe immune acute toxicity in metastatic non-small cell lung cancer patients treated with PD-1 immune checkpoint inhibitors.
Cystatin C
Immune checkpoint inhibitors/adverse effects
Immune checkpoint inhibitors/toxicity
Lung neoplasms
Sarcopenia
Journal
Clinical nutrition (Edinburgh, Scotland)
ISSN: 1532-1983
Titre abrégé: Clin Nutr
Pays: England
ID NLM: 8309603
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
received:
19
10
2022
revised:
14
03
2023
accepted:
29
03
2023
medline:
16
6
2023
pubmed:
27
4
2023
entrez:
26
4
2023
Statut:
ppublish
Résumé
Sarcopenia has long been associated with higher toxicity induced by anti-cancer treatments and shorter survival in patients with solid tumors. The creatinine-to-cystatin ratio (CC ratio, serum creatinine/cystatin C × 100) and the sarcopenia index (SI, serum creatinine × cystatin C (CysC)-based glomerular filtration rate (eGFR From the prospective CERTIM cohort, we analyzed retrospectively stage IV NSCLC patients, who received PD-1 inhibitors between June 2015 and November 2020 in Cochin Hospital (Paris, France). We assessed sarcopenia measuring skeletal muscle area (SMA) by computed tomography and handgrip strength (HGS) by a hand dynamometer. In total, 200 patients were analyzed. The CC ratio and the IS were significantly correlated with SMA and HGS: r In metastatic NSCLC patients treated with PD-1 inhibitors, a lower CC ratio and a lower SI are independent predictors of mortality. However, they are not associated with severe irAEs.
Sections du résumé
BACKGROUND & AIMS
Sarcopenia has long been associated with higher toxicity induced by anti-cancer treatments and shorter survival in patients with solid tumors. The creatinine-to-cystatin ratio (CC ratio, serum creatinine/cystatin C × 100) and the sarcopenia index (SI, serum creatinine × cystatin C (CysC)-based glomerular filtration rate (eGFR
METHODS
From the prospective CERTIM cohort, we analyzed retrospectively stage IV NSCLC patients, who received PD-1 inhibitors between June 2015 and November 2020 in Cochin Hospital (Paris, France). We assessed sarcopenia measuring skeletal muscle area (SMA) by computed tomography and handgrip strength (HGS) by a hand dynamometer.
RESULTS
In total, 200 patients were analyzed. The CC ratio and the IS were significantly correlated with SMA and HGS: r
CONCLUSIONS
In metastatic NSCLC patients treated with PD-1 inhibitors, a lower CC ratio and a lower SI are independent predictors of mortality. However, they are not associated with severe irAEs.
Identifiants
pubmed: 37099986
pii: S0261-5614(23)00104-8
doi: 10.1016/j.clnu.2023.03.023
pii:
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Cystatin C
0
Programmed Cell Death 1 Receptor
0
Creatinine
AYI8EX34EU
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
944-953Informations de copyright
Copyright © 2023 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of interest Jérôme Alexandre received honoraria from Astra Zeneca, MSD, GSK, Eisai, Clovis and Novartis. Marco Alifano received consulting fees from Roche and Astra Zaneca, honoraria from Roche, Astra Zaneca and AMGEN and travel accommodation from Medtronic. Jennifer Arrondeau received honoraria from BMS and Astra Zaneca and meeting accommodation from Pfizer. Pascaline Boudou-Rouquette received personal fees from Takeda, Pharmama and IPSEN. Diane Damotte received a research grant from Astra Zaneca. François Goldwasser served on advisory board for Fresenius Kabi and Nutricia and received research grant from Baxter International Inc, USA. Olivier Huillard received honoraria from Bristol-Myers Squibb, Astellas, IPSEN, MSD, Pfizer, Janssen, Astra Zaneca, Bayer and AAA Novartis and travel accommodation from IPSEN and AAA Novartis. Elisabeth Ashton, Laure Hirsch, Anne Jouinot, Audrey Lupo-Mansuet, Guillaume Ulmann and Marie Wislez have no conflict of interest to declare.